Table 2.

Primary efficacy endpoint analysis (Propensity Score–Matched Efficacy Set).

	Regdanvimab (n = 113)	Control (n = 161)	Difference	P-value*
Patients with severe/critical disease or death due to SARS-CoV-2 infection up to Day 28, n (%) [95% CI]	8 (7.1) [3.6%,13.4%†]	26 (16.1) [11.3%, 22.6%†]	−9.1% [−16.7%, −0.6%‡]	0.0263

CI, confidence interval.

^*P values derived from Fisher’s exact test.

^†Wilson (score) 95% CI is presented.

^‡Farrington and Manning score exact 95% CI for proportion difference is presented.